Table 2.
Incidence of CHF based on prespecified subgroups
| Grades | Subgroup | Number of trials | CHF events | Total number of patients | I2 (%) | Incidence (95% CI) | P for group difference |
|---|---|---|---|---|---|---|---|
| All grade | Overall | 27 | 174 | 6903 | 90 | 3.2 (1.8, 5.8) | NA |
| Tumour types | |||||||
| RCC | 10 | 119 | 5228 | 96 | 4.5 (1.4, 13.6) | 0.52 | |
| Non-RCC | 17 | 55 | 1675 | 63 | 3.0 (1.7, 5.1) | ||
| VEGFR-TKIs | |||||||
| Sunitinib | 14 | 136 | 5638 | 94.3 | 3.6 (1.4, 8.8) | 0.025 | |
| Sorafenib | 4 | 9 | 269 | 66.2 | 3.4 (0.9, 12.5) | ||
| Axitinib | 2 | 3 | 114 | 0 | 2.7 (0.9, 8.1) | ||
| Cediranib | 2 | 6 | 99 | 48.0 | 5.9 (1.5, 20.6) | ||
| Vandetanib | 1 | 1 | 231 | 0 | 0.4 (0.1, 3.0) | ||
| Pazopanib | 3 | 18 | 314 | 0 | 6.1 (3.9, 9.5) | ||
| Ramucirumab | 1 | 1 | 238 | 0 | 0.4 (0.1, 2.9) | ||
| Phase of trials | |||||||
| Phase II | 21 | 45 | 1240 | 32.8 | 4.5 (3.1, 6.6) | 0.42 | |
| Phase III | 6 | 129 | 5663 | 97.8 | 2.4 (0.5, 10.2) | ||
| High grade | Overall | 26 | 48 | 6896 | 58 | 1.4 (0.9, 2.3) | NA |
| Tumour types | |||||||
| RCC | 10 | 35 | 5219 | 0 | 1.8 (0.7, 4.4) | 0.55 | |
| Non-RCC | 16 | 13 | 1677 | 96 | 1.3 (0.8, 2.0) | ||
| VEGFR-TKIs | |||||||
| Sunitinib | 15 | 37 | 5724 | 74.2 | 1.5 (0.7, 3.1) | 0.72 | |
| Sorafenib | 3 | 3 | 238 | 0 | 1.5 (0.5, 4.5) | ||
| Axitinib | 1 | 1 | 52 | 0 | 1.9 (0.3, 12.4) | ||
| Cediranib | 2 | 2 | 99 | 0 | 2.0 (0.5, 7.7) | ||
| Vandetanib | 1 | 1 | 231 | 0 | 0.4 (0.1, 3.0) | ||
| Pazopanib | 3 | 4 | 314 | 0 | 1.5 (0.6, 3.7) | ||
| Ramucirumab | 1 | 0 | 238 | 0 | 0 | ||
| Phase of trials | |||||||
| Phase II | 19 | 16 | 1147 | 97.4 | 2.1 (1.4, 3.3) | 0.18 | |
| Phase III | 7 | 32 | 5749 | 0 | 0.9 (0.3, 2.8) | ||
RCC, renal cell carcinoma; NA, not available.